Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 25, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

COVID-19

Interventions

DRUG

Nitazoxanide Tablets

Patients will receive nitazoxanide 600 mg BID for 7 days

DRUG

Placebo

Patients will receive placebo BID for 7 days

Trial Locations (3)

Hospital Vera Cruz, Campinas

Centro de Genomas, São Paulo

Hospital Emílio Ribas, São Paulo

All Listed Sponsors

collaborator

Farmoquimica S.A.

INDUSTRY

collaborator

Hospital Vera Cruz

OTHER

collaborator

Hospital Casa de Saúde - Vera Cruz - Campinas - SP - Brazil

UNKNOWN

collaborator

Centro de Genomas - UNIFESP

UNKNOWN

collaborator

Emilio Ribas Institute of Infectious Diseases

OTHER

lead

Azidus Brasil

INDUSTRY

NCT04348409 - Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19 | Biotech Hunter | Biotech Hunter